Latest Conference Articles

New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.

Sandip Patel, MD, discusses key unmet needs and open questions surrounding EGFR-mutant NSCLC that has transformed to SCLC.

Alissa Cooper, MD, discusses evolving strategies for biomarker-driven patient selection with tarlatamab in small cell lung cancer.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX in pancreatic adenocarcinoma.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.

Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress

In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.

Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.

First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.

Longer duration of adjuvant FOLFOX and atezolizumab was associated with improved DFS in a retrospective analysis of the ATOMIC trial.

Adagrasib in combination with cetuximab did not significantly improve OS or PFS in KRAS G12C–mutated metastatic colorectal cancer.

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Elisrasib produced a 58.8% ORR and 12.2-month median PFS in KRAS G12C inhibitor–naive NSCLC and remained active in G12C inhibitor–refractory disease.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

Lena Specht, MD, DMSc, discusses data for mogamulizumab in Danish patients with mycosis fungoides or Sezary syndrome and their effect on clinical practice.

Robert Stuver, MD, discusses how to approach treatment for primary cutaneous peripheral T-cell lymphoma and which factors to consider.

H. Miles Prince, MD, MBBS discusses data for mogamulizumab from MAVORIC vs real-world vorinostat in R/R MF and SS.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Neha Mehta-Shah, MD, MSCI explains how rational combinations to overcome CTCL treatment resistance keep running into added toxicity.

Real-world treatment with pegylated interferon alfa-2a tolerable, and treatment-related AEs were manageable in patients with cutaneous T-cell lymphoma.

Julia Scarisbrick, MD, explains how better recognition of mogamulizumab-associated rash is moving the drug earlier in the mycosis fungoides and Sézary treatment course.

Julia Scarisbrick reviews real-world data showing mogamulizumab eased itch, pain, flaking, sleep, and fatigue in MF and Sézary syndrome as early as 4 weeks.

Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.